Search

everythinglearnresearchcommunity

for

Search:↓

Hair regrowth in alopecia universalis may be possible by altering immune cells.

RAGE is a potential target for melanoma treatment, but its effectiveness is uncertain due to variable expression levels.

In June 2019, the stem cell research field saw major progress, including new clinical trials, FDA approvals, and industry collaborations.

Some patients developed hair loss after islet cell transplant possibly due to their immune-suppressing medications.

The document explains how the immune system reacts to organ transplants and the treatments used to prevent rejection.

Monoclonal antibodies LT-1, LT-2, and LT-7 help diagnose certain blood cancers.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.

Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.

Rituximab effectively treated a woman's bone lymphoma that was resistant to other treatments.

Tislelizumab can cause cutaneous lupus erythematosus.

Belimumab reduces disease activity, steroid use, and flares in lupus patients.

Belimumab may cause hair loss in lupus patients.

Donor lymphocyte infusions effectively treated leukemia relapse but caused vitiligo and alopecia areata.

Selective immunotherapies like anifrolumab and belimumab are more effective for treating systemic lupus erythematosus than traditional drugs.

Tph cells are linked to the severity of systemic lupus erythematosus.

Dupilumab successfully treated a woman's alopecia areata and bullous pemphigoid, leading to full hair regrowth and symptom resolution.

Anti-CD19 therapy may help treat SLE and NMOSD.

A woman had a rare skin condition with recurring painful nodules that heal in 6 weeks, often without needing treatment.

Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.

A woman with lupus had blood cell destruction, treated successfully with medication.

Anti-MND antibodies are present in various diseases, not just PBC, and their levels don't correlate with disease activity or skin symptoms.

Three characteristics of plasmacytoid dendritic cells help tell apart lupus-related hair loss from LPP.

CD4+ lymphocytopenia can occur in patients with systemic lupus erythematosus.

SLE can cause unusual gastrointestinal symptoms, and immunosuppressive therapy can be effective.

Catalytic antibodies are early indicators and active participants in the development of systemic lupus erythematosus.

Skin lymphoproliferative disorders are hard to diagnose and often linked to systemic diseases, but most have a good prognosis with accurate diagnosis.

An elderly woman's upper lip lump, thought to be a mucocele, was actually a rare type of lymphoma usually found on legs, treated successfully with chemotherapy and radiation.

Oncology specialists are disappointed by the discontinuation of the effective lymphoma treatment Bexxar.

Pulsed dye laser treatment was effective for a skin condition resistant to other treatments.